<DOC>
	<DOCNO>NCT00295412</DOCNO>
	<brief_summary>The lifetime substance use disorder schizophrenia close 50 % . Substance abuse schizophrenia associate negative consequence . Unfortunately , clear guideline pharmacological treatment dual diagnosis population . Preliminary result suggest second-generation antipsychotic drug ( mainly clozapine ) may relieve drug craving schizophrenia . We perform 12-week pilot study evaluate impact quetiapine , second-generation antipsychotic , substance abuse parameter , psychiatric symptom side effect patient schizophrenia comorbid substance use disorder . Our expectation 20 % decrease drug craving baseline end-point .</brief_summary>
	<brief_title>The Impact Quetiapine Drug Abuse Patterns Addicted Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients schizophrenia spectrum disorder Patients comorbid substance use disorder Patients already quetiapine clozapine Patients hospitalize acutely ill Total score lower 65 PANSS Pregnancy Female subject childbearing potential without adequate contraception Abnormal liver function ( hepatic enzymes 3 time upper normal limit ) Any clinically meaningful unstable renal , hepatic , cardiovascular , respiratory , cerebrovascular disease serious , progressive physical disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>